Navigation Links
WEHI Spin-Out MuriGen Restructures G-CSF Antagonist Program With CSL

MELBOURNE, Australia, Oct. 27 /PRNewswire/ -- MuriGen Therapeutics today announced that its collaboration with CSL for the development of a new class of drugs that target arthritis and other inflammatory diseases has been restructured.

The collaboration was initially established in February 2006 by MuriGen Therapeutics and Zenyth Therapeutics Limited (now part of CSL Limited) and is developing therapeutic antibodies that inhibit the activity of the cytokine granulocyte colony stimulating factor (G-CSF).

The collaboration built on the discovery by Professor Ian Wicks, a clinical rheumatologist at the Walter and Eliza Hall Institute (WEHI) that antagonism of G-CSF or its receptor could ameliorate inflammatory conditions such as rheumatoid arthritis.

Under the terms of the restructure, CSL will now take full control of the program, including development and commercialisation of any potential drugs arising from the program. In return, MuriGen will receive certain payments - the details of which are undisclosed.

Dr Nick Samaras, MuriGen's Chief Executive Officer, said, "We are extremely pleased that the further development of the G-CSF inflammatory disease program will be conducted by an Australian biopharmaceutical partner with the expertise and capability that CSL provide. This partnership is another major milestone for MuriGen and is further evidence of the high quality portfolio the company has in-licensed from the Walter and Eliza Hall Institute. MuriGen will continue to focus on its other programs, including the development of a novel class of antiapoptotic compounds."

"This is an important step in the translation of the Institute's intellectual property," explains Dr Julian Clark, Head of Business Development at WEHI. Clark continues, "Starfish Ventures' investment in MuriGen enabled us to bring this project to a stage where CSL can now use their considerable resources and track record to progress development towards the clinic."

Dr Andrew Cuthbertson, Director of R&D at CSL said, "The G-CSF inflammatory disease project is an excellent example of the strength of Australian medical research. We look forward to a continuing collaboration with our academic colleagues as we take this program into early stage development."

About MuriGen Therapeutics

MuriGen Therapeutics is an Australian-based drug discovery and development company established by the Walter and Eliza Hall Institute of Medical Research and four of its leading scientists. MuriGen is building a portfolio of novel drugs for unmet medical needs across a number of therapeutic areas including arthritis, thrombocytopenia, inflammation, epilepsy and thalassemia. By leveraging its proprietary drug discovery platform, MuriGen Therapeutics is working towards the validation of novel drug targets that have the potential to provide significant benefits for researchers, health care practitioners, and patients. Further information about MuriGen Therapeutics can be found at

About WEHI

The Walter and Eliza Hall Institute of Medical Research (WEHI) is one of the world's leading medical research centres. WEHI's international reputation has been built upon major contributions to immunology, haematology, cancer, malaria and autoimmune diseases, including diabetes, multiple sclerosis, coeliac disease and rheumatoid arthritis. Over many decades, advances and discoveries in these areas have led to significant benefits for patients throughout the world. WEHI is in the front line of the biotechnology revolution, using advances in genetics, bioinformatics and structural biology to help develop individualised therapies and more effective drugs. Further information about WEHI can be found at

Further information:

Dr Nick Samaras

Chief Executive Officer

MuriGen Pty Ltd

+61 3 9345 2115


Dr Julian Clark

Head Business Development

Walter and Eliza Hall Institute of Medical Research

+61 3 9345 2612

SOURCE Walter and Eliza Hall Institute
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. VaxGen Restructures Board of Directors
2. Genta Restructures Operations to Focus on Priority Initiatives
3. Progen Restructures Manufacturing and Drug Discovery Divisions
4. Kosan Restructures Workforce to Focus Resources on Lead Clinical Programs
5. CME LLC Restructures, Announces Its New Executive Management Team
6. Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
7. VaxGen Further Restructures to Preserve Cash as It Pursues Strategic Initiatives
8. ChemoCentryx Advances Second Orally Available CCR9 Antagonist CCX025 Into Clinical Development
9. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
10. Sensitivity Enhancements to Monograms Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy
11. Brain Fitness Program Offers Hope for Breast Cancer Survivors Suffering From Chemobrain
Post Your Comments:
(Date:11/24/2015)... 24, 2015 Cepheid (NASDAQ: CPHD ) ... the following conference, and invited investors to participate via ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern ... New York, NY      Tuesday, December 1, ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... But unless it is bound to proteins, copper is also toxic to cells. ... at Worcester Polytechnic Institute (WPI) will conduct a systematic study of copper in ...
(Date:11/24/2015)... 2015  Clintrax Global, Inc., a worldwide provider of clinical research ... announced that the company has set a new quarterly earnings record ... quarter growth posted for Q3 of 2014 to Q3 of 2015. ... Mexico , with the establishment of an Asia-Pacific ... United Kingdom and Mexico ...
(Date:11/24/2015)... , ... November 24, 2015 , ... The Academy of ... Interest Group (SIG), MultiGP, also known as Multirotor Grand Prix, to represent the First–Person ... few years. Many AMA members have embraced this type of racing and several new ...
Breaking Biology Technology:
(Date:10/27/2015)... -- Munich, Germany , October ... automatically maps data from mobile eye tracking videos created ... that they can be quantitatively analyzed with SMI,s analysis ... , October 28-29, 2015. SMI,s Automated Semantic Gaze ... tracking videos created with SMI,s Eye Tracking Glasses ...
(Date:10/26/2015)...  Delta ID Inc., a company focused on bringing ... devices, announced its ActiveIRIS® technology powers the iris recognition ... by NTT DOCOMO, INC in Japan ... to include iris recognition technology, after a very successful ... May 2015, world,s first smartphone to have this capability. ...
(Date:10/22/2015)... SYNA ), a leading developer of human interface solutions, today reported ... --> --> Net revenue for ... comparable quarter last year to $470.0 million. Net income for the ... diluted share. --> --> ... 39 percent over the prior year period to $56.9 million, or ...
Breaking Biology News(10 mins):